A serum miRNAs signature for early diagnosis of bladder cancer

• Published in: Annals of medicine (Helsinki) Vol. 55; no. 1; pp. 736 - 745
• Main Authors: Yu, Zuhu, Lu, Chong, Lai, Yongqing
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.12.2023; Taylor & Francis Group
• Subjects: Area Under Curve; Bladder cancer; Combined Modality Therapy; diagnosis; Early Detection of Cancer; Humans; MicroRNAs; miRNA; serum biomarker; Urinary Bladder Neoplasms; diagnosis; miRNA; Bladder cancer; serum biomarker
• ISSN: 0785-3890; 1365-2060; 1365-2060
• DOI: 10.1080/07853890.2023.2172206

Bladder cancer accounts for the most common type of urologic malignancy and presents high recurrence rate after surgical resection and adjuvant intravesical therapy. We aim to search for an early diagnostic biomarker in serum for bladder cancer in this study. The expression profiles of miRNAs in serum samples of 112 bladder cancer patients and 112 healthy controls were detected with real-time polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve and area under curve (AUC) analysis were performed to assess the diagnostic efficiency of miRNAs. Stepwise logic regression analysis was used to construct a diagnostic signature with highest sensitivity and specificity. Bioinformatics analysis was applied to explore the potential biological functions and mechanisms of candidate miRNAs. Five miRNAs including miR-451a, miR-381-3p, miR-223-3p, miR-142-5p and miR-27b-3p were found differentially expressed in serum samples of bladder patients and healthy subjects. The diagnostic signature was constructed with miR-27b-3p, miR-381-3p and miR-451a. AUC of the three-miRNA signature was 0.894 (0.837-0.936, p < 0.001). The sensitivity and specificity of this signature were 86.90% and 77.38%, respectively, indicating that this signature has a good ability to diagnose bladder cancer. The three-miRNA signature we constructed has favorable diagnostic capacity and may be a promising non-invasive biomarker in the early diagnosis of bladder cancer. KEY MESSAGES There is still no clinical utilization of serum miRNAs in the early detection of bladder cancer. We screened and constructed a three-miRNA signature with the sensitivity of 86.90% and specificity of 77.38% which may be a promising non-invasive biomarker in the early diagnosis of bladder cancer.